APO-LISDEXAMFETAMINE 60 MG
LISDEXAMFETAMINE DIMESYLATE : 60 MG · DIN 02469014 · APOTEX INC
Health Canada status: APPROVED
What is APO-LISDEXAMFETAMINE?
APO-LISDEXAMFETAMINE 60 MG contains LISDEXAMFETAMINE DIMESYLATE : 60 MG. It is listed in the Health Canada Drug Product Database under DIN 02469014, held by APOTEX INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as approved, status dated 03-Jun-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02469014 |
|---|---|
| Brand name | APO-LISDEXAMFETAMINE |
| Generic / active ingredient | LISDEXAMFETAMINE DIMESYLATE : 60 MG |
| Manufacturer | APOTEX INC |
| Strength | 60 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | CONTROLLED DRUGS (CDSA I) |
| ATC code | N06BA12 LISDEXAMFETAMINE |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 03-Jun-2024 |
What can be used instead?
Other Canadian products sharing ATC code N06BA12 LISDEXAMFETAMINE. 66 of 87 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-LISDEXAMFETAMINE | 10 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02537567 |
| AG-LISDEXAMFETAMINE | 20 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02537575 |
| AG-LISDEXAMFETAMINE | 30 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02537583 |
| AG-LISDEXAMFETAMINE | 40 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02537591 |
| AG-LISDEXAMFETAMINE | 50 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02537605 |
| AG-LISDEXAMFETAMINE | 60 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02537613 |
| APO-LISDEXAMFETAMINE CAPSULES | 10 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02546647 |
| APO-LISDEXAMFETAMINE CAPSULES | 20 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02546655 |
| APO-LISDEXAMFETAMINE CAPSULES | 30 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02546663 |
| APO-LISDEXAMFETAMINE CAPSULES | 40 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02546671 |
Who else supplies LISDEXAMFETAMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LISDEXAMFETAMINE appears in 57 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.